Adaptin Bio (APTN) Income from Continuing Operations (2023 - 2026)

Adaptin Bio has disclosed Income from Continuing Operations across 4 years of filings, most recently posting 1146096.0 for Q1 2026.

• Quarterly Income from Continuing Operations fell 90.04% year-over-year to 1146096.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5743012.0 (down 69.6% YoY) and the FY2025 annual result came in at 5200000.0, down 66.53% from the prior year.
• Income from Continuing Operations rose to 1146096.0 in Q1 2026, from 1400449.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 34155.0 in Q4 2023 and bottomed at 1675612.0 in Q3 2025.
• The 4-year median for Income from Continuing Operations is 856836.0 (2024), against an average of 867795.09.
• Year-over-year, Income from Continuing Operations sank 2479.42% in 2024 and plunged 51.29% in 2025.
• Adaptin Bio's Income from Continuing Operations stood at 34155.0 in 2023, then sank by 2408.67% to 856836.0 in 2024, then tumbled by 63.44% to 1400449.0 in 2025, then grew by 18.16% to 1146096.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 1146096.0, 1400449.0, and 1675612.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.